Breaking News

Gilead Buys Genentech Clinical Facility

Will use the facility for manufacture of investigational cancer drug

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Gilead Sciences will purchase a clinical biologics manufacturing facility and certain process development assets in Oceanside, CA from Genentech, a member of the Roche Group. The agreement covers Genentech’s Oceanside Clinical Plant (OCP), a 70,000-sq.-ft. facility and certain process development assets. Gilead will hire approximately 55 Genentech manufacturing specialists and process development scientists familiar with the facilities to assist with operations. The OCP facility is currently pr...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters